# G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma

> **NCT07184788** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Navy General Hospital, Beijing** · enrollment: 80 (estimated)

## Conditions studied

- Aggressive B-Cell Lymphoma

## Interventions

- **DRUG:** Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy

## Key facts

- **NCT ID:** NCT07184788
- **Lead sponsor:** Navy General Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2030-10-01
- **Final completion:** 2031-10-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07184788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07184788, "G-Pola-GemOx in Refractory/Relapsed Aggressive B-Cell Lymphoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07184788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*